Related Experiment Video
Updated: Dec 26, 2025
Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
Published on: September 22, 2020
Rationale and design of the granulocyte-macrophage colony stimulating factor in peripheral arterial disease (GPAD-3)
Anurag Mehta1, Kreton Mavromatis2, Yi-An Ko3
1Emory Clinical Cardiovascular Research Institute, Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia.
Insights
This study investigates Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) to improve walking ability in peripheral arterial disease (PAD) patients. Two GM-CSF administrations aim to alleviate claudication symptoms in lower extremity PAD.
Area of Science:
- Vascular Medicine
- Regenerative Medicine
- Clinical Trials
Background:
- Peripheral arterial disease (PAD) significantly impacts public health, with many patients experiencing debilitating claudication.
- Current medical and surgical treatments often fail to fully alleviate PAD symptoms.
- Mobilizing endogenous progenitor cells with Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) presents a novel therapeutic avenue.
Purpose of the Study:
- To evaluate the efficacy of two successive administrations of GM-CSF in improving claudication among patients with lower extremity PAD.
- To assess the potential of GM-CSF as an alternative therapy for PAD symptom management.
- To provide data supporting a potential pivotal Phase III trial for GM-CSF in PAD.
Main Methods:
- A randomized, double-blind, placebo-controlled Phase IIB trial involving 176 patients with lower extremity PAD.
- Participants receive subcutaneous injections of GM-CSF (500 μg/day for three weeks) or placebo, with a second administration after 3 months.
- The primary endpoint is the change in 6-minute walk distance from baseline to the 6-month follow-up.
Main Results:
- Data collection and analysis are ongoing for the GPAD-3 trial.
- Preliminary findings from earlier phase trials suggest promising results for GM-CSF in experimental models.
- The study is designed to determine the clinical effectiveness of GM-CSF in improving ambulatory function.
Conclusions:
- The GPAD-3 trial explores a novel therapeutic strategy for alleviating claudication in lower extremity PAD.
- Successful outcomes could establish GM-CSF as a viable treatment option, potentially leading to larger-scale clinical trials.
- This research addresses the unmet need for effective therapies in managing PAD symptoms.
Background:
Lower extremity peripheral arterial disease (PAD) is a public health problem and many patients with PAD experience claudication despite adequate medical and/or surgical management. Mobilization of endogenous progenitor cells using Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) is a novel therapeutic option that has shown promising results in experimental models and phase I/IIA clinical trials. The GPAD-3 trial will study the effect of two successive administrations of GM-CSF at 3-month interval for improving claudication among patients with lower extremity PAD.
Methods:
We plan to recruit 176 patients in this ongoing randomized, double-blind, placebo-controlled Phase IIB trial. After screening for inclusion and exclusion criteria, eligible subjects undergo a 4-week screening phase where they perform subcutaneous placebo injections thrice weekly and walk at least three times a day until they develop claudication. After the screening phase, eligible subjects undergo baseline testing and are randomized 2:1 to receive 500 μg/day of GM-CSF subcutaneously thrice weekly for three weeks or placebo injections. After 3 months, follow-up endpoint testing is performed and subjects in the GM-CSF group receive the second administration of the drug for three weeks while subjects in placebo group receive matching placebo injections. All participants undergo endpoint testing at six-month and nine-month follow-up. The primary endpoint is change in 6-min walk distance between baseline and 6-month follow-up.
Conclusion:
GPAD-3 explores a novel approach to address the need for alternative therapies that can alleviate symptoms among patients with lower extremity PAD. If successful, this study will pave the way for a pivotal Phase III trial.
Related Concept Videos
01:27Peripheral Artery Disease III: Interprofessional Care
01:30Peripheral Artery Disease I: Introduction
01:26Peripheral Artery Disease IV: Nursing Management
01:15Differentiation of Common Myeloid Progenitor Cells
01:21Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
01:01Regulation of Hematopoietic Stem Cells